These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17099832)

  • 21. Relevance of the BONN Risk Index for metabolic monitoring of patients with calcium oxalate urolithiasis: a clinical application study of the Urolizer.
    Berg W; Bechler R; Haas C; Laube N
    Urol Res; 2009 Apr; 37(2):55-62. PubMed ID: 19205684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary metabolic evaluations in solitary and recurrent stone forming children.
    DeFoor W; Minevich E; Jackson E; Reddy P; Clark C; Sheldon C; Asplin J
    J Urol; 2008 Jun; 179(6):2369-72. PubMed ID: 18433777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of urinary stones on the composition of a 24-hour urine sample.
    Laube N; Pullmann M; Hergarten S; Hesse A
    Clin Chem; 2003 Feb; 49(2):281-5. PubMed ID: 12560352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of laser-probe and photometric determination of the urinary crystallization risk of calcium oxalate.
    Laube N; Hergarten S; Hesse A
    Clin Chem Lab Med; 2002 Jun; 40(6):595-9. PubMed ID: 12211654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Personal experience in the diagnosis and monitoring of therapy in metabolic disorders with risk of crystallization in patients with recurrent urolithiasis].
    Stejskal D; Bártek J; Hrebícek J; Bána J; Zát'ura F; Mohapl P; Terber R
    Vnitr Lek; 1997 Dec; 43(12):781-6. PubMed ID: 9601889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A form of premorbid condition of urolithiasis and urinary stone composition in children with urolithiasis].
    Jung A; Kamińska A; Olszewski S; Rutka J
    Pol Merkur Lekarski; 2000 Apr; 8(46):188-90. PubMed ID: 10897606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Normative data on the Bonn Risk Index for calcium oxalate crystallization in healthy children.
    Porowski T; Zoch-Zwierz W; Wasilewska A; Spotyk A; Konstantynowicz J
    Pediatr Nephrol; 2007 Apr; 22(4):514-20. PubMed ID: 17216257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body size and 24-hour urine composition.
    Taylor EN; Curhan GC
    Am J Kidney Dis; 2006 Dec; 48(6):905-15. PubMed ID: 17162145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor.
    Rodgers A; Allie-Hamdulay S; Jackson G
    Nephrol Dial Transplant; 2006 Feb; 21(2):361-9. PubMed ID: 16249202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The most important factor for active urinary stone formation in patients with urolithiasis].
    Simić-Ogrizović S; Dopsaj V; Jovicić S; Milenković D; Jovanović D; Nesić V
    Med Pregl; 2007; 60 Suppl 2():117-20. PubMed ID: 18928175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of stone disease.
    Porena M; Guiggi P; Micheli C
    Urol Int; 2007; 79 Suppl 1():37-46. PubMed ID: 17726351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin resistance and low urinary citrate excretion in calcium stone formers.
    Cupisti A; Meola M; D'Alessandro C; Bernabini G; Pasquali E; Carpi A; Barsotti G
    Biomed Pharmacother; 2007 Jan; 61(1):86-90. PubMed ID: 17184967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary risk factors for recurrent calcium stone formation in Thai stone formers.
    Stitchantrakul W; Kochakarn W; Ruangraksa C; Domrongkitchaiporn S
    J Med Assoc Thai; 2007 Apr; 90(4):688-98. PubMed ID: 17487123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Problems in the investigation of urine from patients suffering from primary hyperoxaluria type 1.
    Laube N; Hoppe B; Hesse A
    Urol Res; 2005 Nov; 33(5):394-7. PubMed ID: 16151774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluid intake and epidemiology of urolithiasis.
    Siener R; Hesse A
    Eur J Clin Nutr; 2003 Dec; 57 Suppl 2():S47-51. PubMed ID: 14681713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of inositol hexaphosphate (phytate) on calcium binding, calcium oxalate crystallization and in vitro stone growth.
    Saw NK; Chow K; Rao PN; Kavanagh JP
    J Urol; 2007 Jun; 177(6):2366-70. PubMed ID: 17509360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical management of calcium oxalate urolithiasis.
    Gerstenbluth RE; Resnick MI
    Med Clin North Am; 2004 Mar; 88(2):431-42. PubMed ID: 15049586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel method of imaging calcium urolithiasis using fluorescence.
    Figueiredo JL; Passerotti CC; Sponholtz T; Nguyen HT; Weissleder R
    J Urol; 2008 Apr; 179(4):1610-4. PubMed ID: 18295253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of lithogenic risk in children based on a morning spot urine sample.
    Porowski T; Kirejczyk JK; Zoch-Zwierz W; Konstantynowicz J; Korzeniecka-Kozerska A; Motkowski R; Laube N
    J Urol; 2010 Nov; 184(5):2103-8. PubMed ID: 20850811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.